Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
上 海 復 星 醫 藥( 集 團 )股 份 有 限 公 司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02196)
INTERIM RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED 30 JUNE 2021
The board (the ''Board'') of directors (the ''Directors'') of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') is pleased to announce the unaudited interim results of the Company and its subsidiaries (collectively, the ''Group'') for the six months ended 30 June 2021 (the ''Reporting Period'').
- 1 -
FINANCIAL HIGHLIGHTS
Interim Condensed Consolidated Statement of Profit or Loss
For the six months ended 30 June 2021
For the six months ended 30 June | |||||
2021 | 2020 | ||||
Notes | RMB'000 | RMB'000 | |||
(Unaudited) | (Unaudited) | ||||
REVENUE | 4 | 16,877,537 | 13,965,179 | ||
Cost of sales | (8,110,878) | (6,215,872) | |||
Gross profit | 8,766,659 | 7,749,307 | |||
Other income | 5 | 141,714 | 180,429 | ||
Selling and distribution expenses | (4,356,975) | (3,931,067) | |||
Administrative expenses | (1,505,057) | (1,322,239) | |||
Research and development expenses | (1,561,885) | (1,204,425) | |||
Impairment losses on financial assets | (14,804) | (42,765) | |||
Other gains | 6 | 1,645,255 | 603,622 | ||
Other expenses | (338,367) | (52,138) | |||
Interest income | 116,605 | 96,436 | |||
Finance costs | 7 | (420,725) | (427,878) | ||
Share of profits and losses of: | |||||
Joint ventures | (93,817) | (46,558) | |||
Associates | 925,626 | 698,964 | |||
PROFIT BEFORE TAX | 8 | 3,304,229 | 2,301,688 | ||
Income tax expense | 9 | (550,647) | (392,081) | ||
PROFIT FOR THE PERIOD | 2,753,582 | 1,909,607 | |||
Attributable to: | |||||
Owners of the parent | 2,482,373 | 1,714,710 | |||
Non-controlling interests | 271,209 | 194,897 | |||
2,753,582 | 1,909,607 | ||||
EARNINGS PER SHARE ATTRIBUTABLE TO | |||||
ORDINARY EQUITY HOLDERS OF THE PARENT | 11 | ||||
Basic | |||||
- For profit for the period | RMB0.97 Yuan | RMB0.67 Yuan | |||
Diluted | |||||
- For profit for the period | RMB0.97 Yuan | RMB0.67 Yuan | |||
- 2 -
Interim Condensed Consolidated Statement of Comprehensive Income
For the six months ended 30 June 2021
For the six months ended 30 June | ||||
2021 | 2020 | |||
RMB'000 | RMB'000 | |||
(Unaudited) | (Unaudited) | |||
PROFIT FOR THE PERIOD | 2,753,582 | 1,909,607 | ||
OTHER COMPREHENSIVE INCOME | ||||
Other comprehensive loss that may be reclassified to profit or | ||||
loss in subsequent periods: | ||||
Exchange differences on translation of foreign operations | (201,712) | (255,609) | ||
Share of other comprehensive loss of joint ventures | (804) | (1,115) | ||
Share of other comprehensive income of associates | 54,912 | 29,073 | ||
Net other comprehensive loss that may be reclassified to | ||||
(147,604) | ||||
profit or loss in subsequent periods | (227,651) | |||
Other comprehensive income that will not be reclassified to | ||||
profit or loss in subsequent periods: | ||||
Equity investments designated at fair value through | ||||
other comprehensive income | 5,200 | |||
Changes in fair value | 3,727 | |||
Income tax effect | (780) | 24 | ||
4,420 | 3,751 | |||
Share of other comprehensive income of associates | 10,725 | 68,933 | ||
Net other comprehensive income that will not be reclassified to | 15,145 | |||
profit or loss in subsequent periods | 72,684 | |||
OTHER COMPREHENSIVE LOSS FOR THE PERIOD, | ||||
(132,459) | ||||
NET OF TAX | (154,967) | |||
TOTAL COMPREHENSIVE INCOME | ||||
FOR THE PERIOD | 2,621,123 | 1,754,640 | ||
Attributable to: | 2,385,072 | |||
Owners of the parent | 1,660,547 | |||
Non-controlling interests | 236,051 | 94,093 | ||
2,621,123 | 1,754,640 | |||
- 3 -
Interim Condensed Consolidated Statement of Financial Position
30 June 2021
30 June | 31 December | |||
2021 | 2020 | |||
Notes | RMB'000 | RMB'000 | ||
(Unaudited) | (Audited) | |||
NON-CURRENT ASSETS | ||||
Property, plant and equipment | 11,986,909 | 12,579,873 | ||
Right-of-use assets | 2,574,667 | 2,666,402 | ||
Goodwill | 8,622,217 | 8,677,249 | ||
Other intangible assets | 9,730,364 | 9,577,741 | ||
Investments in joint ventures | 349,077 | 381,616 | ||
Investments in associates | 22,447,860 | 21,870,966 | ||
Equity investments designated at fair value | ||||
through other comprehensive income | 6,243 | 1,043 | ||
Financial assets at fair value through profit or loss | 1,459,128 | 1,460,769 | ||
Deferred tax assets | 232,984 | 244,937 | ||
Other non-current assets | 1,807,055 | 1,083,724 | ||
Total non-current assets | 59,216,504 | 58,544,320 | ||
CURRENT ASSETS | ||||
Inventories | 5,485,618 | 5,162,800 | ||
Trade and bills receivables | 12 | 6,028,237 | 4,807,059 | |
Prepayments, other receivables and other assets | 3,462,140 | 2,554,165 | ||
Financial assets at fair value through profit or loss | 3,267,854 | 1,970,096 | ||
Debt investments at fair value through | ||||
other comprehensive income | 472,998 | 628,881 | ||
Cash and bank balances | 10,489,133 | 9,961,802 | ||
Total current assets | 29,205,980 | 25,084,803 |
- 4 -
30 June | 31 December | |||
2021 | 2020 | |||
Notes | RMB'000 | RMB'000 | ||
(Unaudited) | (Audited) | |||
CURRENT LIABILITIES | ||||
Trade and bills payables | 13 | 3,745,584 | 3,289,021 | |
Other payables and accruals | 6,582,248 | 5,597,564 | ||
Interest-bearing bank and other borrowings | 15,852,411 | 14,488,946 | ||
Lease liabilities | 140,052 | 151,084 | ||
Contract liabilities | 1,447,288 | 1,020,309 | ||
Tax payable | 389,670 | 325,429 | ||
Total current liabilities | 28,157,253 | 24,872,353 | ||
NET CURRENT ASSETS | 1,048,727 | 212,450 | ||
TOTAL ASSETS LESS CURRENT LIABILITIES | 60,265,231 | 58,756,770 | ||
NON-CURRENT LIABILITIES | ||||
Interest-bearing bank and other borrowings | 8,513,509 | 8,475,685 | ||
Lease liabilities | 706,945 | 627,291 | ||
Deferred tax liabilities | 2,935,378 | 2,852,997 | ||
Deferred income | 506,250 | 482,201 | ||
Other long term liabilities | 277,854 | 269,488 | ||
Contract liabilities | 285,708 | 121,712 | ||
Total non-current liabilities | 13,225,644 | 12,829,374 | ||
Net assets | 47,039,587 | 45,927,396 | ||
EQUITY | ||||
Equity attributable to owners of the parent | ||||
Issued share capital | 2,562,899 | 2,562,899 | ||
Reserves | 35,241,150 | 34,375,748 | ||
37,804,049 | 36,938,647 | |||
Non-controlling interests | 9,235,538 | 8,988,749 | ||
Total equity | 47,039,587 | 45,927,396 |
- 5 -
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 23 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 August 2021 03:43:03 UTC.